Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
07 déc. 2021 16h15 HE
|
Daré Bioscience, Inc.
Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosisThis marks the first FDA-approved product in Daré’s portfolio of potential first...
Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update
10 nov. 2021 08h00 HE
|
Daré Bioscience, Inc.
Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3 ...
Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
09 nov. 2021 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021
03 nov. 2021 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience to Participate in Panel Discussion at DTC Perspectives’ Xpectives.Health Summit, October 12-14, 2021
06 oct. 2021 08h51 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in DTC Perspectives’ Xpectives.Health...
Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1
27 sept. 2021 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver...
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy
23 sept. 2021 08h00 HE
|
Daré Bioscience, Inc.
Investigational therapy for women who cannot, or should not, take supplemental estrogen Potential to be the first treatment for vulvar and vaginal atrophy specifically developed for patients with...
Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference
22 sept. 2021 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
08 sept. 2021 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
Daré Bioscience to Participate in Panel Discussion at Women’s Health Innovation Summit
07 sept. 2021 08h00 HE
|
Daré Bioscience, Inc.
The discussion, Women’s Health Case Study: Optimizing Study Enrollment During the COVID-19 Pandemic, will review the DARE-BVFREE Phase 3 study that was successfully initiated and completed during 2020...